Clinical trial
Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and…
NCT00034385 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00034385 |
|---|---|
| Title | Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients |
| Official title | Pharmacokinetics of Valganciclovir in Kidney and Kidney/Pancreas Transplant Recipients |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Kidney Trasplant |
| Intervention type | Drug |
| Interventions | Valganciclovir |
| Enrollment | 12 |
| Start date | Apr 24, 2002 |
| Primary completion | Jan 30, 2007 |
| Completion | Oct 30, 2009 |
| First posted | Apr 29, 2002 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: